Previous 10 | Next 10 |
home / stock / govxw / govxw news
Phase 2 Vaccine Designed to Enhance Response for Immunocompromised Patients Complements GeoVax’s Pan-Coronavirus Vaccine Program ATLANTA, GA and DUARTE, CA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs Inc. (Nasdaq: GOVX), ...
Conference call to be held Thursday, November 11, at 4:30 p.m. Eastern Time ATLANTA, GA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing hum...
GEO-CM02 Progresses as a Universal Coronavirus Vaccine Candidate ATLANTA, GA, Oct. 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today ann...
Single-dose of GEO-EM01 Provided 100% Protection in Lethal Challenge Evaluation Atlanta, GA, Oct. 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against inf...
License of Gedeptin® Adds Orphan Drug Clinical Program for Treatment of Advanced Head and Neck Cancers ATLANTA, GA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in d...
Atlanta, GA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc . (Nasdaq: GOVX), a biotechnology company developing human vaccines and cancer immunotherapies, announces today that Chairman & CEO David Dodd will present at the H.C. Wainwright 23rd An...
ATLANTA, GA, Aug. 19, 2021 (GLOBE NEWSWIRE) -- GeoVax Vaccine Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and c...
ATLANTA, GA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers, today announced that it will be presenting at the SNN Network Summer Virtual ...
Continued Progress on COVID-19 and Immuno-Oncology Programs ATLANTA, GA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers,...
Conference call to be held Wednesday, August 11, at 4:30 p.m. Eastern Time ATLANTA, GA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing huma...
News, Short Squeeze, Breakout and More Instantly...
GeoVax Labs Inc. Warrants Company Name:
GOVXW Stock Symbol:
NASDAQ Market:
GeoVax Labs Inc. Warrants Website:
Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced ...
ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will presen...
ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36t...